{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T08:04:24Z","timestamp":1771056264245,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04270-2","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:15:23Z","timestamp":1771053323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25"],"prefix":"10.1007","volume":"75","author":[{"given":"Giandomenico","family":"Roviello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Gambale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"De Gennaro Aquino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismaela Anna","family":"Vascotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Erbetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Mennitto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Elena","family":"Rebuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Nasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariella","family":"Sorar\u00f9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Scolari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinella Micol","family":"Mela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Salfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rametta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Cerbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Doni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"3","key":"4270_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5152\/tud.2023.23023","volume":"49","author":"D Enneli","year":"2023","unstructured":"Enneli D, Baglan T (2023) The many faces of urothelial carcinomas: an update from pathology to clinical approach and challenges in practice. Urol Res Pract 49(3):147\u2013161. https:\/\/doi.org\/10.5152\/tud.2023.23023","journal-title":"Urol Res Pract"},{"key":"4270_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103682","volume":"174","author":"M Audisio","year":"2022","unstructured":"Audisio M, Tucci M, Di Stefano RF, Parlagreco E, Ungaro A, Turco F, Audisio A, Di Prima L, Ortega C, Di Maio M, Scagliotti GV, Buttigliero C (2022) New emerging targets in advanced urothelial carcinoma: is it the primetime for personalized medicine? Crit Rev Oncol Hematol 174:103682. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103682","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"4270_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","volume":"21","author":"G Roviello","year":"2024","unstructured":"Roviello G, Santoni M, Sonpavde GP, Catalano M (2024) The evolving treatment landscape of metastatic urothelial cancer. Nat Rev Urol 21(10):580\u2013592. https:\/\/doi.org\/10.1038\/s41585-024-00872-0","journal-title":"Nat Rev Urol"},{"issue":"3","key":"4270_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.eururo.2022.09.002","volume":"83","author":"A Necchi","year":"2023","unstructured":"Necchi A, Bamias A, Sonpavde G et al (2023) Clinical impact of site-specific metastases in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors: a meta-analysis of individual patient data from five trials. Eur Urol 83(3):239\u2013246. https:\/\/doi.org\/10.1016\/j.eururo.2022.09.002","journal-title":"Eur Urol"},{"issue":"3","key":"4270_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.juro.2016.09.075","volume":"197","author":"G Sonpavde","year":"2017","unstructured":"Sonpavde G, Pond GR, Rosenberg JE et al (2017) Prognostic impact of sites of visceral metastasis in patients with urothelial carcinoma treated with second-line chemotherapy or immunotherapy. J Urol 197(3):593\u2013600. https:\/\/doi.org\/10.1016\/j.juro.2016.09.075","journal-title":"J Urol"},{"issue":"10","key":"4270_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069908","volume":"13","author":"J Zhang","year":"2023","unstructured":"Zhang J, Cai D, Hong S (2023) Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: a population-based study. BMJ Open 13(10):e069908. https:\/\/doi.org\/10.1136\/bmjopen-2022-069908","journal-title":"BMJ Open"},{"issue":"1","key":"4270_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6073-7","volume":"19","author":"MA Bilen","year":"2019","unstructured":"Bilen MA, Shabto JM, Martini DJ, Liu Y, Lewis C, Collins H, Akce M, Kissick H, Carthon BC, Shaib WL, Alese OB, Steuer CE, Wu C, Lawson DH, Kudchadkar R, Master VA, El-Rayes B, Ramalingam SS, Owonikoko TK, Harvey RD (2019) Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer 19(1):857. https:\/\/doi.org\/10.1186\/s12885-019-6073-7","journal-title":"BMC Cancer"},{"key":"4270_CR8","doi-asserted-by":"publisher","unstructured":"Roviello G, Gambale E, Aquino IG, Maruzzo M, Messina C, Vascotto IA, Rossi V, Bimbatti D, Erbetta E, Messina M, Mennitto A, Rebuzzi SE, Nasso C, Mercinelli C, Maiorano BA, Fanelli M, Sorar\u00f9 M, Scolari F, Mela MM, Galli L, Salfi A, Rizzo M, Puglisi S, Orlando V, Fornarini G, Rametta A, Giannatempo P, Cerbone L, Doni L, Pillozzi S, Antonuzzo L. (2025) Real-World Effectiveness of Avelumab Maintenance in Advanced Urothelial Carcinoma: Results from the Italian Multicenter MALVA Study (Meet-URO 25). Oncologist. Nov 20:oyaf388. https:\/\/doi.org\/10.1093\/oncolo\/oyaf388.","DOI":"10.1093\/oncolo\/oyaf388"},{"key":"4270_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E et al (2016) RECIST 1.1 \u2013 update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"issue":"4","key":"4270_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nrc.2017.126","volume":"18","author":"KW Hunter","year":"2018","unstructured":"Hunter KW, Amin R, Deasy S, Ha NH, Wakefield L (2018) Genetic insights into the morass of metastatic heterogeneity. Nat Rev Cancer 18(4):211\u2013223. https:\/\/doi.org\/10.1038\/nrc.2017.126","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4270_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01576-4","volume":"8","author":"H Ji","year":"2023","unstructured":"Ji H, Hu C, Yang X, Liu Y, Ji G, Ge S, Wang X, Wang M (2023) Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. Signal Transduct Target Ther 8(1):367. https:\/\/doi.org\/10.1038\/s41392-023-01576-4","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4270_CR12","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2017.321","volume":"11","author":"F Macedo","year":"2017","unstructured":"Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F (2017) Bone metastases: an overview. Oncol Rev 11(1):321. https:\/\/doi.org\/10.4081\/oncol.2017.321. (eCollection 2017 Mar 3.)","journal-title":"Oncol Rev"},{"issue":"13","key":"4270_CR13","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383(13):1218\u20131230. https:\/\/doi.org\/10.1056\/NEJMoa2002788","journal-title":"N Engl J Med"},{"key":"4270_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.05.017","author":"J Bellmunt","year":"2025","unstructured":"Bellmunt J, Powles T, Park SH, Voog E, Valderrama BP, Gurney H, Ull\u00e9n A, Loriot Y, Sridhar SS, Tsuchiya N, Sternberg CN, Aragon-Ching JB, Petrylak DP, Climent Duran MA, Tyroller K, Hoffman J, Jacob N, Grivas P, Gupta S (2025) Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN bladder 100 trial in patients with nonvisceral or lymph node-only disease. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.017. (Online ahead of print.)","journal-title":"Eur Urol"},{"issue":"5","key":"4270_CR15","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.3390\/curroncol28050290","volume":"28","author":"S Tsukamoto","year":"2021","unstructured":"Tsukamoto S, Kido A, Tanaka Y, Facchini G, Peta G, Rossi G, Mavrogenis AF (2021) Current overview of treatment for metastatic bone disease. Curr Oncol 28(5):3347\u20133372. https:\/\/doi.org\/10.3390\/curroncol28050290","journal-title":"Curr Oncol"},{"key":"4270_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100405","volume":"31","author":"M Stellato","year":"2021","unstructured":"Stellato M, Santini D, Cursano MC, Foderaro S, Tonini G, Procopio G (2021) Bone metastases from urothelial carcinoma. The dark side of the moon. J Bone Oncol 31:100405. https:\/\/doi.org\/10.1016\/j.jbo.2021.100405. (eCollection 2021 Dec.)","journal-title":"J Bone Oncol"},{"issue":"19","key":"4270_CR17","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, \u00dcr\u00fcn Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD, CheckMate 901 Trial Investigators (2023) Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 389(19):1778\u20131789. https:\/\/doi.org\/10.1056\/NEJMoa2309863. (Epub 2023 Oct 22.)","journal-title":"N Engl J Med"},{"key":"4270_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.04.019","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, van der Heijden MS, Powles T, Claps M, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, \u00dcr\u00fcn Y, Ye D, Valderrama BP, Tomita Y, Jiang R, Filian J, Wang L, van Kooten Losio M, Sonpavde G (2025) Characterization of patients with lymph node only metastatic urothelial carcinoma treated with nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone from the CheckMate 901 trial. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2025.04.019. (Online ahead of print.)","journal-title":"Eur Urol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04270-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04270-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04270-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:15:23Z","timestamp":1771053323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04270-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4270"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04270-2","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GR: Scientific advisory boards, consulting, travel expenses: MSD, Merck Serono, Bayer, BMS, AAA, Astra Zeneca, Pfizer, Astellas DB has served in consulting or advisory roles for Astellas Pharma, Eisai, Gentili, Ipsen, Janssen, Merck, MSD, Novartis, and Pfizer. LC: Scientific advisory boards, consulting, travel expenses: MSD, Merck Serono, Bayer, BMS, AAA, Astra Zeneca, Pfizer, Astellas LA: Payment or honoraria for lectures and presentation: Astra Zeneca, Roche, Astellas, Novartis, MSD, BMS, Ipsen, Merck Serono, Amgen, Bayer; Support For Attending Meeting And\/Or Travel Grant: Astra Zeneca, Novartis, Ipsen, Merck Serono; Research Founding To My Institution: Novartis, Astra Zeneca  MaMa served as advisor for MSD, BMS, Merck Serono, AZ, J&J, Astellas, EISAI, Recordati; FP served as advisor for J&J, Astellas  SER received honoraria as speaker at scientific events, editorial projects and travel accommodation from BMS, MSD, Janssen, Astellas, Ipsen, GSK, Amgen  CN received honoraria as speaker and travel accomodation from MSD, Astellas, Ipsen, GSK, Johnson&Johson, BMS   The other authors declare no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"79"}}